Regulus Therapeutics Stock Price, News & Analysis (NASDAQ:RGLS) $1.28 -0.03 (-2.29%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$1.23▼$1.3250-Day Range$1.21▼$1.4452-Week Range$0.76▼$2.14Volume20,430 shsAverage Volume41,073 shsMarket Capitalization$25.88 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Regulus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside720.3% Upside$10.50 Price TargetShort InterestHealthy1.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.08Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.58) to ($1.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.45 out of 5 starsMedical Sector191st out of 949 stocksPharmaceutical Preparations Industry77th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingRegulus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Regulus Therapeutics has a forecasted upside of 720.3% from its current price of $1.28.Amount of Analyst CoverageRegulus Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.04% of the float of Regulus Therapeutics has been sold short.Short Interest Ratio / Days to CoverRegulus Therapeutics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Regulus Therapeutics has recently decreased by 5.18%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegulus Therapeutics does not currently pay a dividend.Dividend GrowthRegulus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RGLS. Previous Next 3.4 News and Social Media Coverage News SentimentRegulus Therapeutics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Regulus Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for RGLS on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regulus Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.41% of the stock of Regulus Therapeutics is held by insiders.Percentage Held by Institutions62.22% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Regulus Therapeutics are expected to grow in the coming year, from ($1.58) to ($1.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regulus Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Regulus Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRegulus Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Regulus Therapeutics Stock (NASDAQ:RGLS)Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More RGLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGLS Stock News HeadlinesNovember 24, 2023 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.comNovember 22, 2023 | finance.yahoo.comRegulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNovember 29, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.November 11, 2023 | markets.businessinsider.comRegulus Stock Maintains Buy Rating Amid Financial Stability and Positive Clinical Trial ProgressNovember 9, 2023 | finance.yahoo.comRegulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent UpdatesNovember 2, 2023 | finance.yahoo.comRegulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)October 19, 2023 | finance.yahoo.comRegulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)October 5, 2023 | nasdaq.comRegulus Therapeutics (RGLS) Price Target Increased by 13.64% to 6.38November 29, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.September 22, 2023 | msn.comCanaccord Genuity Maintains Regulus Therapeutics (RGLS) Buy RecommendationSeptember 21, 2023 | markets.businessinsider.comAnalyst Expectations for Regulus Therapeutics's FutureSeptember 20, 2023 | msn.comRegulus Therapeutics Releases Early Data From Of Investigational For Rare Type Of Kidney DiseaseSeptember 20, 2023 | markets.businessinsider.comRegulus Reports Positive Topline Data From First Cohort Of Patients In Phase 1b Study Of RGLS8429September 20, 2023 | finance.yahoo.comRegulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)September 13, 2023 | finance.yahoo.comRegulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)September 5, 2023 | finance.yahoo.comRegulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesAugust 24, 2023 | gurufocus.comRegulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap?August 23, 2023 | finance.yahoo.comRegulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to OutperformanceAugust 23, 2023 | finance.yahoo.comRegulus Therapeutics to Host Virtual Investor Event on September 6, 2023August 9, 2023 | markets.businessinsider.comRegulus (RGLS) Gets a Buy from H.C. WainwrightAugust 8, 2023 | finance.yahoo.comRegulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent UpdatesAugust 2, 2023 | finance.yahoo.comRegulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferenceJuly 18, 2023 | finance.yahoo.comRegulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney ConferenceJune 28, 2023 | markets.businessinsider.comExpert Ratings for Regulus TherapeuticsJune 28, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Regulus (RGLS)June 27, 2023 | finance.yahoo.comRegulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)June 23, 2023 | finance.yahoo.comRegulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of DirectorsSee More Headlines Receive RGLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RGLS CUSIP75915K10 CIK1505512 Webwww.regulusrx.com Phone(858) 202-6300FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price Target$10.50 High Stock Price Target$12.00 Low Stock Price Target$9.00 Potential Upside/Downside+720.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-94.24% Return on Assets-69.69% Debt Debt-to-Equity RatioN/A Current Ratio4.25 Quick Ratio4.25 Sales & Book Value Annual Sales$10.01 million Price / Sales2.59 Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book0.56Miscellaneous Outstanding Shares20,220,000Free Float18,522,000Market Cap$25.88 million OptionableOptionable Beta1.61 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Joseph P. Hagan M.B.A. (Age 54)CEO & Director Comp: $920.73kMs. Crispina Calsada CPA (Age 53)Chief Financial Officer Comp: $500.87kMr. Christopher Ray Aker J.D. (Age 62)Senior VP, General Counsel & Corporate Secretary Comp: $524.79kDr. Preston S. Klassen M.D. (Age 54)M.H.S., President and Head of Research & Development Mr. Daniel J. Penksa (Age 37)Executive Director of Finance & Controller Dr. Claire Susan Padgett M.S.M.T., Ph.D., Senior Vice President of Clinical OperationsDr. Rekha Garg M.D.M.S., Senior Vice President of Clinical Development & RegulatoryMore ExecutivesKey CompetitorsMolecular TemplatesNASDAQ:MTEMBolt BiotherapeuticsNASDAQ:BOLTFortress BiotechNASDAQ:FBIOCatalyst BiosciencesNASDAQ:CBIOEmergent BioSolutionsNYSE:EBSView All CompetitorsInstitutional OwnershipFMR LLCBought 716,000 shares on 11/13/2023Ownership: 14.454%Victory Capital Management Inc.Bought 11,701 shares on 11/6/2023Ownership: 1.197%View All Institutional Transactions RGLS Stock Analysis - Frequently Asked Questions Should I buy or sell Regulus Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RGLS shares. View RGLS analyst ratings or view top-rated stocks. What is Regulus Therapeutics' stock price target for 2024? 2 brokers have issued 1-year price objectives for Regulus Therapeutics' shares. Their RGLS share price targets range from $9.00 to $12.00. On average, they predict the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 720.3% from the stock's current price. View analysts price targets for RGLS or view top-rated stocks among Wall Street analysts. How have RGLS shares performed in 2023? Regulus Therapeutics' stock was trading at $1.37 at the beginning of the year. Since then, RGLS stock has decreased by 6.6% and is now trading at $1.28. View the best growth stocks for 2023 here. When is Regulus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our RGLS earnings forecast. How were Regulus Therapeutics' earnings last quarter? Regulus Therapeutics Inc. (NASDAQ:RGLS) announced its quarterly earnings data on Wednesday, November, 10th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by $0.20. During the same quarter in the prior year, the business posted ($0.40) earnings per share. When did Regulus Therapeutics' stock split? Regulus Therapeutics shares reverse split before market open on Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO? 2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Regulus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN). Who are Regulus Therapeutics' major shareholders? Regulus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.45%), Victory Capital Management Inc. (1.20%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher Ray Aker, Denis Drygin, Joseph P Hagan and Paul Edward Walker. View institutional ownership trends. How do I buy shares of Regulus Therapeutics? Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:RGLS) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.